Skip to content

Clinical Study for the Prognostic Effect of IgA and Non-IgA Classification in Multiple Myeloma

Clinical Study for the Prognostic Effect of IgA and Non-IgA Classification in Multiple Myeloma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900026611
Enrollment
Unknown
Registered
2019-10-16
Start date
2020-01-01
Completion date
Unknown
Last updated
2019-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

IgA and non-IgA classification of multiple myeloma:N/A

Sponsors

The First Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: According to the Guidelines for Diagnosis and Treatment of Multiple Myeloma in China (revised in 2017), National Comprehensive Cancer Network (NCCN) and European Society of Oncology Internal Medicine (ESMO) guidelines in 2017, patients with multiple myeloma have been diagnosed in our hospital since May 2008.

Exclusion criteria

Exclusion criteria: According to the Guidelines for Diagnosis and Treatment of Multiple Myeloma (revised in 2017) and National Comprehensive Cancer Network (NCCN) and European Society of Oncology Internal Medicine (ESMO) guidelines in 2017, smoking myeloma and solitary plasmacytoma (skeletal and extraskeletal) patients and those clinical diagnosis and treatment data are obviously incomplete.

Design outcomes

Primary

MeasureTime frame
serum protein electrophoresis (M protein);immunofixation electrophoresis;immune eight items;serum free light chain;serum ß2 microglobulin;bone marrow plasma cell percentage;bone marrow immunotyping;bone marrow chromosomal;

Countries

China

Contacts

Public ContactHuasheng Liu

The First Affiliated Hospital of Xi'an Jiaotong University

Lhs681995@126.com+86 18991232963

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026